Mineralys Therapeutics Inc.

6 clinical trials · Sponsor

Record	Firm	Date
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension (NCT06785454)	Mineralys Therapeutics Inc.	2025-02-28
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria (NCT06150924)	Mineralys Therapeutics Inc.	2023-12-14
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension (NCT06153693)	Mineralys Therapeutics Inc.	2023-11-22
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension (NCT05968430)	Mineralys Therapeutics Inc.	2023-07-14
A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen (NCT05769608)	Mineralys Therapeutics Inc.	2023-03-13
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension (NCT05001945)	Mineralys Therapeutics Inc.	2021-07-01

Every clearance here is in the API, with alerts when new ones post.